Brown Advisory Securities’s Nymox Pharmaceutical Corp NYMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-28,000
| Closed | -$12K | – | 138 |
|
|
2022
Q2 | $12K | Hold |
28,000
| – | – | 0.01% | 140 |
|
|
2022
Q1 | $35K | Hold |
28,000
| – | – | 0.02% | 171 |
|
|
2021
Q4 | $36K | Hold |
28,000
| – | – | 0.02% | 217 |
|
|
2021
Q3 | $58K | Hold |
28,000
| – | – | 0.02% | 237 |
|
|
2021
Q2 | $44K | Hold |
28,000
| – | – | 0.01% | 256 |
|
|
2021
Q1 | $62K | Hold |
28,000
| – | – | 0.01% | 249 |
|
|
2020
Q4 | $69K | Hold |
28,000
| – | – | 0.01% | 248 |
|
|
2020
Q3 | $69K | Hold |
28,000
| – | – | 0.01% | 231 |
|
|
2020
Q2 | $92K | Hold |
28,000
| – | – | 0.02% | 230 |
|
|
2020
Q1 | $60K | Hold |
28,000
| – | – | 0.02% | 224 |
|
|
2019
Q4 | $62K | Hold |
28,000
| – | – | 0.01% | 242 |
|
|
2019
Q3 | $51K | Hold |
28,000
| – | – | 0.01% | 228 |
|
|
2019
Q2 | $41K | Hold |
28,000
| – | – | 0.01% | 248 |
|
|
2019
Q1 | $55K | Hold |
28,000
| – | – | 0.01% | 280 |
|
|
2018
Q4 | $44K | Hold |
28,000
| – | – | 0.01% | 350 |
|
|
2018
Q3 | $69K | Hold |
28,000
| – | – | 0.01% | 381 |
|
|
2018
Q2 | $94K | Hold |
28,000
| – | – | 0.02% | 372 |
|
|
2018
Q1 | $118K | Hold |
28,000
| – | – | 0.02% | 352 |
|
|
2017
Q4 | $92K | Hold |
28,000
| – | – | 0.02% | 356 |
|
|
2017
Q3 | $107K | Hold |
28,000
| – | – | 0.02% | 343 |
|
|
2017
Q2 | $123K | Hold |
28,000
| – | – | 0.03% | 324 |
|
|
2017
Q1 | $102K | Hold |
28,000
| – | – | 0.03% | 315 |
|
|
2016
Q4 | $75K | Hold |
28,000
| – | – | 0.02% | 298 |
|
|
2016
Q3 | $91K | Hold |
28,000
| – | – | 0.03% | 280 |
|
|
2016
Q2 | $94K | Hold |
28,000
| – | – | 0.03% | 271 |
|
|
2016
Q1 | $68K | Hold |
28,000
| – | – | 0.02% | 265 |
|
|
2015
Q4 | $92K | Hold |
28,000
| – | – | 0.03% | 258 |
|
|
2015
Q3 | $96K | Hold |
28,000
| – | – | 0.03% | 269 |
|
|
2015
Q2 | $37K | Hold |
28,000
| – | – | 0.01% | 295 |
|
|
2015
Q1 | $24K | Hold |
28,000
| – | – | 0.01% | 296 |
|
|
2014
Q4 | $11K | Buy |
28,000
+12,000
| +75% | +$25.6K | ﹤0.01% | 300 |
|
|
2014
Q3 | $70K | Buy |
16,000
+5,000
| +45% | +$24.5K | 0.03% | 264 |
|
|
2014
Q2 | $55K | Hold |
11,000
| – | – | 0.02% | 279 |
|
|
2014
Q1 | $60K | Buy |
11,000
+1,000
| +10% | +$5.8K | 0.02% | 258 |
|
|
2013
Q4 | $61K | Buy |
+10,000
| New | +$68.2K | 0.02% | 253 |
|
Other funds holding NYMX
FDCDDQ
LSA
GG
FCFC
Brown Advisory Securities's NYMX Position: Q3 2022 in Review
Brown Advisory Securities sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2022, closing a stake of 28,000 shares — an estimated $12K sold.
Brown Advisory Securities first reported a position in NYMX in Q4 2013 and held it in 35 quarters. The position peaked at $123K in Q2 2017. 34 funds tracked by Wall St. Rank hold NYMX as of Q3 2022.
- Brown Advisory Securities reported no remaining Nymox Pharmaceutical Corp position as of Q3 2022 after selling out during the quarter.
- Brown Advisory Securities sold 28,000 Nymox Pharmaceutical Corp shares in Q3 2022, an estimated $12K.
- Brown Advisory Securities first reported a position in Nymox Pharmaceutical Corp in Q4 2013 and held it in 35 quarters.
- Brown Advisory Securities's Nymox Pharmaceutical Corp position peaked at $123K in Q2 2017.
- 34 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2022.
Based on Brown Advisory Securities's 13F filing for Q3 2022, filed 14 Nov 2022.